Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200 at the EULAR 2026 Congress in London, UK, from June 3-6, 2026. LFD-200 is a novel subcutaneously administered ADC that delivers a potent glucocorticoid directly to immune cells. The Phase 1 data from healthy participants showed that LFD-200 was well tolerated and demonstrated dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
The presentation at EULAR 2026 highlighted key findings from the initial Phase 1 cohort, indicating that LFD-200 has a favorable safety profile and does not cause the cortisol suppression typically associated with systemic glucocorticoid therapy. This is a significant advancement, as current glucocorticoid treatments for rheumatoid arthritis and other inflammatory conditions often lead to serious side effects due to systemic exposure. By targeting the drug directly to immune cells, LFD-200 aims to maximize therapeutic benefit while minimizing toxicity.
Lifordi is currently dosing patients with moderate to severe rheumatoid arthritis in the Phase 1 study, with data expected by the end of 2026. The company's approach leverages the success of ADCs in oncology, applying the technology to autoimmune diseases. LFD-200 is the lead candidate in Lifordi's pipeline, which also includes ADCs with antisense oligonucleotides, siRNA, and small molecules.
Lifordi is backed by prominent investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures. The company is committed to transforming the treatment landscape for immune and inflammatory diseases. For more information, visit www.lifordi.com and follow on LinkedIn.
